Algert Global LLC Holds Position in Pfenex Inc (PFNX)
Algert Global LLC maintained its stake in Pfenex Inc (NYSEMKT:PFNX) during the second quarter, Holdings Channel reports. The firm owned 34,603 shares of the biotechnology company’s stock at the end of the second quarter. Algert Global LLC’s holdings in Pfenex were worth $139,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of PFNX. Sanders Morris Harris LLC boosted its stake in Pfenex by 79.9% in the second quarter. Sanders Morris Harris LLC now owns 745,687 shares of the biotechnology company’s stock valued at $2,990,000 after buying an additional 331,167 shares in the last quarter. Sanders Morris Harris Inc. increased its position in Pfenex by 12.4% in the first quarter. Sanders Morris Harris Inc. now owns 414,520 shares of the biotechnology company’s stock valued at $2,408,000 after buying an additional 45,796 shares during the last quarter. FMR LLC increased its position in Pfenex by 25.7% in the first quarter. FMR LLC now owns 344,677 shares of the biotechnology company’s stock valued at $2,003,000 after buying an additional 70,577 shares during the last quarter. Renaissance Technologies LLC increased its position in Pfenex by 148.5% in the first quarter. Renaissance Technologies LLC now owns 325,800 shares of the biotechnology company’s stock valued at $1,893,000 after buying an additional 194,700 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd purchased a new position in Pfenex during the first quarter valued at $1,759,000.
Pfenex Inc (NYSEMKT PFNX) opened at 3.90 on Friday. The stock has a market cap of $91.76 million, a P/E ratio of 60.94 and a beta of 4.65. The firm’s 50-day moving average price is $4.31 and its 200 day moving average price is $5.42. Pfenex Inc has a 52-week low of $3.54 and a 52-week high of $11.35.
Pfenex (NYSEMKT:PFNX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.06. Pfenex had a negative net margin of 356.00% and a negative return on equity of 53.20%. The company had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.10 million. During the same quarter last year, the company posted ($0.43) EPS. Pfenex’s revenue was down 3.5% on a year-over-year basis. Equities analysts predict that Pfenex Inc will post ($2.09) earnings per share for the current year.
Several equities analysts recently weighed in on PFNX shares. Zacks Investment Research raised Pfenex from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Wednesday, July 19th. William Blair reaffirmed an “outperform” rating on shares of Pfenex in a research note on Monday, June 26th. Finally, ValuEngine downgraded Pfenex from a “hold” rating to a “sell” rating in a research note on Saturday, June 3rd.
In related news, Director Jason Grenfell-Gardner acquired 10,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was bought at an average price of $4.51 per share, for a total transaction of $45,100.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $45,100. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Pfenex Company Profile
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Want to see what other hedge funds are holding PFNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfenex Inc (NYSEMKT:PFNX).
Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.